Hugo A. Jørgensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hugo A. Jørgensen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rune Andreas Kroken
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
6 shared publications - Else-Marie Løberg
Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway
5 shared publications - Erik Johnsen
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
5 shared publications - Else-Marie Løberg
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; NORMENT Centre of Excellence, University of Oslo, Norway; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Department of Clinical Psychology, University of Bergen, Norway
4 shared publications - Rolf Gjestad
Research Department, Division of Psychiatry, Haukeland University Hospital
4 shared publications - Eirik Kjelby
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
3 shared publications
Latest Publications
- 1 August 2018
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 103, 219-228
Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment
- 1 August 2018
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 103, 219-228
Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment
- Open Access
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
Open AccessThe serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S169-S170
Poster #S221 SUICIDALITY IN SCHIZOPHRENIA SPECTRUM DISORDERS: RELATION TO HALLUCINATIONS AND PERSECUTORY DELUSIONS
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S169-S170
Poster #S221 SUICIDALITY IN SCHIZOPHRENIA SPECTRUM DISORDERS: RELATION TO HALLUCINATIONS AND PERSECUTORY DELUSIONS
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S122-S123
Poster #S94 C-REACTIVE PROTEIN LEVELS ARE INVERSELY ASSOCIATED WITH NEUROCOGNITIVE PERFORMANCE IN ACUTELY ADMITTED PATIENTS WITH PSYCHOSIS
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S122-S123
Poster #S94 C-REACTIVE PROTEIN LEVELS ARE INVERSELY ASSOCIATED WITH NEUROCOGNITIVE PERFORMANCE IN ACUTELY ADMITTED PATIENTS WITH PSYCHOSIS
- Open Access
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Open AccessHallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Corrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Open AccessCorrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Open AccessCorrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 31 August 2011
- Published by Springer Nature in BMC Psychiatry
- Vol. 11 (1) , 145
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial
Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis. Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS). A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01). There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis. ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/ : NCT00932529
- 31 August 2011
- Published by Springer Nature in BMC Psychiatry
- Vol. 11 (1) , 145
Open AccessAnti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial
Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis. Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS). A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01). There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis. ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/ : NCT00932529
- 1 June 2004
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 58 (4) , 313-317
Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals
Since the introduction of chlorpromazine, an increasing number of drugs have been added to the list of antipsychotics (neuroleptics). These drugs can be further classified as either first-generation antipsychotics (FAPs) or second-generation antipsychotics (SAPs), depending on their ability to antagonize serotonine in addition to dopamine. The efficacy of various drugs is generally equal, whereas both pharmacological profiles and side-effects differ. Antipsychotic drug therapy recommendations are available both in Norway and internationally, and the purpose of this cross-sectional survey was to register the use of these drugs in representative mental hospitals (A and B), and compare our findings to the recommendations. Medical prescriptions were registered, and data further analysed. In hospital A, a total of 149 patients' prescriptions were registered. Antipsychotics were received voluntarily by 117 patients. Eighty-two of these used one antipsychotic drug, and in this group, 65% received SAPs. Antipsychotic combination therapy was received by 35 patients, and was associated with higher prescription rates of both anticholinergics and benzodiazepines. SAPs were not associated with increased use of benzodiazepines, compared to FAPs. Antipsychotics were frequently combined with mood stabilizers and antidepressants. Our findings in hospital A concerning therapy practices of antipsychotics, were confirmed in hospital B, where 64 patients' medical prescriptions were registered. We conclude that FAPs are still commonly prescribed. Antipsychotic combination therapy is used despite of lack of evidence for efficacy, and is associated with increased prescription rates of anticholinergics and benzodiazepines.
- 1 June 2004
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 58 (4) , 313-317
Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals
Since the introduction of chlorpromazine, an increasing number of drugs have been added to the list of antipsychotics (neuroleptics). These drugs can be further classified as either first-generation antipsychotics (FAPs) or second-generation antipsychotics (SAPs), depending on their ability to antagonize serotonine in addition to dopamine. The efficacy of various drugs is generally equal, whereas both pharmacological profiles and side-effects differ. Antipsychotic drug therapy recommendations are available both in Norway and internationally, and the purpose of this cross-sectional survey was to register the use of these drugs in representative mental hospitals (A and B), and compare our findings to the recommendations. Medical prescriptions were registered, and data further analysed. In hospital A, a total of 149 patients' prescriptions were registered. Antipsychotics were received voluntarily by 117 patients. Eighty-two of these used one antipsychotic drug, and in this group, 65% received SAPs. Antipsychotic combination therapy was received by 35 patients, and was associated with higher prescription rates of both anticholinergics and benzodiazepines. SAPs were not associated with increased use of benzodiazepines, compared to FAPs. Antipsychotics were frequently combined with mood stabilizers and antidepressants. Our findings in hospital A concerning therapy practices of antipsychotics, were confirmed in hospital B, where 64 patients' medical prescriptions were registered. We conclude that FAPs are still commonly prescribed. Antipsychotic combination therapy is used despite of lack of evidence for efficacy, and is associated with increased prescription rates of anticholinergics and benzodiazepines.